Montelukast modifies simvastatin-induced myopathy and hepatotoxicity

Drug Development Research
Mohammad S HareedyMarwa F Ali

Abstract

Montelukast (MNK) has prominent anti-inflammatory and antioxidant activities. It can protect the liver in different hepatotoxic models in animals. Simvastatin (SMV) is one of commonly used lipid lowering drugs for treatment of dyslipidemia in order to reduce cardiovascular disease. It has severe side effects such as myopathy and hepatotoxicity. The aim of the present study is to investigate the possible effect of MNK on SMV-induced myopathy and hepatotoxicity. Four groups of male rats: control group which received saline via stomach tube, MNK treated group (received 10 mg/kg/day MNK via stomach tube), SMV treated group (received 30 mg/kg/day SMV via stomach tube), and MNK + SMV (combination) group which received both MNK and SMV. All animals were treated for 14 days before obtaining blood and tissue samples. SMV has both hepatotoxic effects and myopathy. SMV caused a significant increase in myoglobin, creatinine kinase, ALT, AST, ALP, and bilirubin but, it decreased total proteins, globulin and albumin levels. Co-treatment of SMV and MNK increased the antioxidant activity significantly. MNK modifies partially the myopathic changes and hepatotoxic effect of SMV. Co-administration of MNK and SMV decreased their toxic potentials o...Continue Reading

References

Mar 26, 2003·The American Journal of Gastroenterology·David A SassTong Wu
May 1, 1959·Archives of Biochemistry and Biophysics·G L ELLMAN
Mar 12, 2004·Expert Opinion on Pharmacotherapy·Anjuli Nayak
Sep 25, 2004·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Mark W RussoPaul Watkins
Dec 13, 2006·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·G C ActisM Rizzetto
Aug 29, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Paul B WatkinsLinda E Kasten
Jun 25, 2009·Journal of Postgraduate Medicine·A HarugeriM Ramesh
Mar 23, 2011·Pathophysiology : the Official Journal of the International Society for Pathophysiology·Ahmed M MohamadinFahad A Al-Abbasi
Dec 24, 2013·Naunyn-Schmiedeberg's Archives of Pharmacology·Ihab T Abdel-Raheem, Naglaa F Khedr
Apr 15, 2014·International Journal of Cardiology·Lianne ParkinG Peter Herbison
Sep 10, 2014·Pharmacology·Gioacchino CalapaiSebastiano Gangemi
Oct 16, 2015·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·Mustafa İçerCahfer Guloglu
Jan 14, 2016·Current Molecular Pharmacology·Neil C Thomson
Feb 15, 2016·International Journal of Cardiology·Beth A TaylorPaul D Thompson
Nov 20, 2016·Liver International : Official Journal of the International Association for the Study of the Liver·Einar S Björnsson
Apr 5, 2017·European Journal of Clinical Pharmacology·Malvina HoxhaAurora Bueno Cavanillas
Sep 14, 2017·Journal of Biochemical and Molecular Toxicology·Amany M GadDalaal M Abdallah
Oct 27, 2017·Journal of Biochemical and Molecular Toxicology·Hayat A Abd El AalHelmy Moawad
Aug 4, 2018·Journal of Hepatology·Elisa PosePere Ginès

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.